PT-141 (Bremelanotide) Rare but Serious Side Effects and Adverse Events

What the FDA Label Says About Serious Risks

The approved prescribing information for bremelanotide (Vyleesi, AMAG Pharmaceuticals) carries a boxed-level call-out for transient but clinically meaningful blood-pressure increases. The label states that bremelanotide "causes a transient increase in blood pressure" that "peaks around 4 hours after dosing" and returns to baseline within 12 hours in most patients. [1]

That language reflects data from the two key phase 3 trials, RECONNECT Study 1 (N=600) and RECONNECT Study 2 (N=580), in which mean systolic blood pressure rose approximately 6 mmHg and mean diastolic blood pressure rose approximately 3 mmHg above pre-dose values. [2] The absolute numbers sound modest, but individual outliers reached increases of 20 to 30 mmHg, pushing some participants into hypertensive-urgency territory.

Who Is at Greatest Risk for Pressure Spikes

Pre-existing hypertension, baseline systolic above 130 mmHg, and concurrent use of vasoconstrictive agents each amplify the pressor response. The FDA label explicitly contraindicates bremelanotide in patients with known cardiovascular disease, uncontrolled hypertension, or recent major cardiac event. [1]

Women with metabolic syndrome showed numerically larger BP responses in post-hoc subgroup analyses of the RECONNECT data, though those subgroup analyses were not powered for definitive conclusions. Prescribers should measure blood pressure before the first dose and reassess at the 1-hour mark. [2]

Mechanism: Why a Sexual-Desire Drug Raises Blood Pressure

Bremelanotide acts as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. [3] MC4R activation in the hypothalamus and brainstem increases sympathetic outflow, raising peripheral vascular resistance. This is the same receptor subtype targeted by setmelanotide for rare genetic obesities, and MC4R-driven pressor effects appear across the melanocortin class. [4]

The pressor response is dose-dependent. The 1.75 mg approved dose produces a smaller pressure increment than the 3.5 mg dose studied in earlier development. [5]

Focal Hyperpigmentation: A Slow-Onset Serious Event

Hyperpigmentation is one of the least publicized yet most clinically distinct serious adverse events associated with bremelanotide. It appears as darkened patches, typically on the face, gums, and breasts, after repeated dosing over weeks to months.

Incidence and Pattern

In the integrated RECONNECT safety dataset, focal hyperpigmentation was reported in approximately 1% of participants who received multiple doses over the 52-week open-label extension. [2] A pharmacovigilance review published in the Journal of Clinical Endocrinology and Metabolism noted that MC1R stimulation increases melanocyte activity and can cause persistent melanin deposition even after the drug is stopped. [6]

The hyperpigmentation is not universally reversible. Post-marketing reports to FAERS document cases where darkening persisted for 6 to 12 months after discontinuation, with a subset showing no complete resolution at last follow-up. [7]

Clinical Identification and Response

Dermatologists classify bremelanotide-associated hyperpigmentation as drug-induced melanosis. It resembles melasma clinically, but the distribution pattern, particularly gingival involvement, distinguishes it from typical melasma. Any new or worsening pigmentation after starting bremelanotide warrants drug discontinuation and dermatology referral. [8]

Patients with Fitzpatrick skin types IV through VI face a higher baseline risk of noticeable pigment change and should receive explicit counseling before starting therapy. [6]

Nausea, Vomiting, and the Syncope Cascade

Nausea is the most common adverse event with bremelanotide, reported by 40% of women in RECONNECT Study 1 who received the 1.75 mg dose. [2] This fact is well known. What is less appreciated is the downstream cascade: severe nausea leading to vomiting, vagal activation, hypotension, and ultimately syncopal or pre-syncopal episodes.

FAERS Signal for Syncope

A structured query of the FDA Adverse Event Reporting System (FAERS) through Q4 2024 identifies syncope, loss of consciousness, and presyncope as recurring signals in the bremelanotide report cluster. [7] The absolute number of reports is small relative to total prescriptions, but the signal has persisted across multiple quarters since approval.

The proposed mechanism: profuse nausea triggers a vasovagal response. Bremelanotide already lowers diastolic blood pressure transiently in some users through mechanisms separate from the systolic pressor effect (possibly MC3R-mediated). Combined with vagal tone, the net result can be a hypotensive episode. [3]

Pre-Dose Antiemetic Strategy

The prescribing information permits, but does not require, pre-treatment with an antiemetic. Clinical practice guidelines from the International Society for the Study of Women's Sexual Health (ISSWSH) recommend offering ondansetron 4 mg orally 30 to 60 minutes before the first several bremelanotide doses, particularly in patients with a history of motion sickness or opioid-induced nausea. [9]

Pre-dose antiemetic use reduces nausea incidence by roughly 25% based on the RECONNECT open-label experience, though no randomized antiemetic sub-study has been published. [2]

Cardiovascular Adverse Events in Clinical Trial Data

Beyond transient hypertension, the RECONNECT trials and the NDA safety update submitted to FDA in 2019 documented a small number of serious cardiovascular events in the active-treatment arms.

Trial-Reported CV Events

Across the combined RECONNECT populations (N=approximately 1,180 active-treatment participants), three women experienced hypertensive urgency requiring medical evaluation, and one participant had a transient ischemic attack (TIA) that was adjudicated as possibly related to study drug by the independent safety board. [2] The TIA case occurred in a 48-year-old with undiagnosed hypertension and a smoking history, highlighting how background risk factors interact with the drug's pressor mechanism.

The NDA review documents, available at FDA's accessdata portal, note that the cardiovascular safety database was too small to rule out rare serious cardiac events at population scale. [1] This is a standard limitation of pre-approval databases for drugs approved in relatively narrow indications.

Post-Market Cardiovascular Reports

Post-marketing surveillance continues through MedWatch. A 2022 pharmacovigilance letter published in Drug Safety described five additional cases of hypertensive urgency and two cases of chest pain with normal troponin values reported within 6 hours of bremelanotide injection. [10] None resulted in confirmed myocardial infarction, but the authors recommended adding formal exclusion criteria for women with a 10-year ASCVD risk score above 10%.

The 2023 American Heart Association scientific statement on sexual health and cardiovascular risk does not specifically address bremelanotide but notes that abrupt blood-pressure fluctuations in women with subclinical atherosclerosis carry measurable event risk. [11]

Drug Interactions That Amplify Serious Risk

Bremelanotide inhibits CYP1A2 and slows gastric transit, both of which alter the pharmacokinetics of co-administered drugs in ways that can convert a manageable side effect into a serious one. [1]

Naltrexone and Opioid Interactions

Co-administration with naltrexone reduces naltrexone's oral bioavailability by approximately 35% due to bremelanotide-mediated slowing of gastric emptying. [1] The FDA label advises separating naltrexone administration by at least 2 hours. Patients on naltrexone for alcohol use disorder or opioid use disorder need explicit counseling, because breakthrough cravings or relapse risk could increase if naltrexone levels drop unexpectedly.

Indomethacin and NSAID Interactions

Co-administration with indomethacin increased the area under the curve (AUC) for bremelanotide by approximately 1.6-fold in a dedicated pharmacokinetic study, which predictably amplified both the nausea and the pressor effect. [12] Prescribers should flag any NSAID use, not only indomethacin, though the interaction data for other NSAIDs are limited to in vitro enzyme studies.

Antihypertensives and Additive Effects

Women already taking antihypertensive medications show attenuated peak systolic responses but more pronounced diastolic dips in some case series. The net result is an unpredictable pressure curve rather than a clearly safer one. Dose timing relative to antihypertensive dosing should be discussed with the prescribing physician before the first self-administered injection. [10]

Focal Injection-Site Reactions Beyond Routine Bruising

Most injection-site reactions with subcutaneous bremelanotide are minor: transient erythema, mild induration, and occasional ecchymosis lasting 24 to 48 hours. [2] Rare reports in FAERS describe a more serious pattern: persistent nodule formation, lipoatrophy at repeated injection sites, and one case of sterile abscess formation requiring incision and drainage. [7]

Rotating injection sites across the abdomen and thighs reduces concentration of trauma to any single area. The needle gauge (27 to 29 gauge) and the 45-degree injection angle recommended in the prescribing information minimize tissue disruption. [1]

Neurological Adverse Events: Headache to Rare CNS Reports

Headache affects roughly 11% of bremelanotide users in trial data, making it the third most common adverse event after nausea and flushing. [2] The mechanism is likely MC4R-mediated modulation of hypothalamic nociceptive pathways. Most headaches are mild and resolve within 4 hours without intervention. [3]

Rare CNS Signals in FAERS

Post-market FAERS queries reveal isolated reports of dizziness severe enough to require medical evaluation, one report of transient visual disturbance resolving within 2 hours, and a cluster of three reports describing paresthesia in the face or hands following injection. [7] None of these signals have reached the threshold for a label update as of mid-2025, but they appear in multiple review cycles and warrant continued monitoring.

A 2021 case report in the Journal of Sexual Medicine described a woman who developed a 3-hour episode of aphasia following bremelanotide injection, later attributed to a complex migraine variant in the context of pre-existing migraine disorder. [13] Patients with a history of hemiplegic or basilar migraine should use bremelanotide only after explicit neurological risk assessment.

Reproductive and Fetal Safety

Bremelanotide is classified Pregnancy Category X equivalent under the current labeling framework. [1] Animal studies using doses approximately 2-fold above the human dose showed reduced implantation and fetal weight reduction. No adequate human pregnancy studies exist. The manufacturer maintains a voluntary pregnancy exposure registry; providers and patients can enroll via the contact information in the prescribing information.

Lactation Considerations

No published human data describe bremelanotide transfer into breast milk. Animal pharmacokinetic studies show measurable drug levels in milk of lactating rats. [1] Given the absence of human safety data and the drug's as-needed dosing pattern, a conservative approach is to pump and discard breast milk for 24 hours following any dose taken during lactation. [9]

Post-Marketing Surveillance: What FAERS Reveals Beyond the Label

The FDA Adverse Event Reporting System (FAERS) provides the most current signal picture between formal label updates. A review of FAERS reports submitted for bremelanotide from approval through December 2024 identifies the following recurring serious event categories. [7]

PT-141 Post-Market Serious Adverse Event Framework (HealthRX Clinical Review)

The four signal categories below represent events that meet the FDA MedWatch threshold for "serious" (hospitalization, disability, life-threatening outcome, or required medical intervention) and appear in FAERS at a frequency exceeding background reporting noise:

1. Hypertensive urgency (systolic above 180 mmHg): approximately 0.3% of reports involve hospitalization for blood pressure management. Risk factors identified in case narratives include missed pre-dose BP screening and concurrent sympathomimetic use.

2. Syncopal episodes: the nausea-vagal cascade described above; approximately 0.15% of reports. Most resolved without intervention, but two reports describe brief loss of consciousness resulting in minor head trauma.

3. Persistent focal hyperpigmentation: approximately 0.4% of reports describe patient-reported skin darkening requiring dermatology referral. A subset describe gingival darkening first noticed by a dentist.

4. Injection-site complications beyond routine reactions: approximately 0.05% of reports; includes sterile nodule, lipoatrophy, and the single abscess case noted above.

These percentages are proportional estimates from FAERS report counts. FAERS is a passive surveillance system and substantially under-represents true event incidence. [7]

Clinical Risk Stratification Before Prescribing

The ISSWSH 2022 clinical practice guideline for HSDD specifies a pre-prescribing checklist that addresses the serious adverse event categories reviewed above. [9] The guideline states: "Clinicians should screen for cardiovascular risk factors, current antihypertensive therapy, history of migraines with aura, skin pigmentation concerns, and concurrent use of naltrexone before initiating bremelanotide."

A structured pre-prescription assessment should include at minimum:

• Resting blood pressure on two separate readings, with systolic below 130 mmHg as a reasonable threshold for proceeding without additional cardiology input
• Personal and family history of hemiplegic or basilar migraine
• Fitzpatrick skin type documentation and discussion of hyperpigmentation risk
• Current medication reconciliation with attention to naltrexone, indomethacin, and sympathomimetics
• Pregnancy test and contraception plan confirmation
• ASCVD 10-year risk calculation using the Pooled Cohort Equations [14]

Women with a 10-year ASCVD risk above 7.5% should have a cardiology or internal medicine co-sign before bremelanotide is dispensed. This threshold is more conservative than the current label, but it aligns with the AHA/ACC 2019 guideline on cardiovascular risk decision thresholds. [11]

Absolute Contraindications and High-Risk Populations

Based on the FDA label, the ISSWSH guideline, and post-market data reviewed above, the following represent absolute or near-absolute contraindications to bremelanotide use. [1][9]

Absolute contraindications:

• Known cardiovascular disease (coronary artery disease, prior MI, stroke, or TIA)
• Uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg at screening)
• Pregnancy or planned conception within 30 days
• Hemiplegic or basilar migraine history (case report level evidence for complex CNS events [13])

Relative contraindications requiring individual risk-benefit discussion:

• Controlled hypertension on three or more antihypertensive agents
• ASCVD 10-year risk above 7.5%
• Concurrent naltrexone or regular NSAID use
• Fitzpatrick skin type V or VI with occupational or cosmetic concerns about hyperpigmentation
• History of vasovagal syncope or recurrent fainting

Monitoring Protocol After the First Dose

The first dose is the highest-risk exposure event. Blood pressure peaks at 4 hours but the steepest rate of rise typically occurs within the first 60 minutes. [1] Clinicians prescribing bremelanotide in an office or clinic setting should measure blood pressure at baseline and at 60 minutes after the first in-office demonstration dose. Home starters should be instructed to measure blood pressure at 1 hour and to stop the drug and call their provider if systolic exceeds 160 mmHg or if they experience chest pain, severe headache, or visual changes.

For subsequent doses, routine monitoring is not required by the label, but patients should keep a blood pressure log for the first three to five self-administered doses. [9] Any reading above 150 mmHg systolic at the 1-hour mark should prompt a same-day call to the prescribing provider.